Please assess the completion status of the following clinical trial:

Trial Title: Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females at least 18 years of age.~* Evidence of nonalcoholic steatohepatitis (NASH) on a liver biopsy performed within six months of entry to this study.~* Laboratory parameters indicative of decompensated liver disease including:~  * bilirubin less than 2 milligrams/decilitre (mg/dl).~ * stable albumin within normal limits.~ * prothrombin time less than 3 seconds prolonged.~* Serum creatinine less than 1.5 times the upper limit of normal.~* Diabetic patients must be stable on oral medication for diabetes or have had less than a 10 percent change in their insulin dose over the past two months.~* Thyroid stimulating hormone (TSH) or Free Thyroxine Index (FTI) within the normal range.~* Hepatitis C antibody negative.~* Hepatitis B Surface Antigen (HBsAg) seronegative.~* Antinuclear antibody (ANA) less than 1:320.~* Patient provides written informed consent.~Exclusion Criteria:~* Alcohol use exceeding 10 to 29 grams per day during the past six months.~* Evidence of a cause of liver disease other than nonalcoholic steatohepatitis (NASH) on liver biopsy including: viral hepatitis, alcoholic liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, or recent hepatoxic drug exposure.~* Patients with cirrhosis.~* Use of medications commonly associated with nonalcoholic steatohepatitis (NASH) including: glucocorticoids, estrogens, tamoxifen, methotrexate, nifedipine, diltiazem, chloroquine, isoniazid, or amiodarone within the past six months.~* Use of non-steroidal antiinflammatory drugs, fibrates (fenofibrate or gemfibrozil) or warfarin within one month of entering the study.~* Uncontrolled diabetes, defined as a glycated hemoglobin (A1C) level greater than 8%.~* Patients with insulin-dependent diabetes.~* History of jejunal-ileal bypass or extensive small bowel resection.~* Substance abuse including, but not limited to, alcohol or intravenous and inhaled drugs within the past six months.~* Use of chemotherapy within six months of enrollment.~* Patients taking metformin.~* Thyroid abnormality in which normal thyroid function cannot be maintained by medication.~* Pregnancy, females who are breastfeeding.~* Solid organ transplant recipient.~* History of a medical condition, which could interfere with participation in and completion of the protocol.~* Use of oral supplements of Vitamin E within one month of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omega-3-acid ethyl esters (Lovaza) (Type: ACTIVE_COMPARATOR): Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive daily placebo and dietary counseling for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).